亞輝龍(688575.SH):擬共同出資500萬元設立煥生紀生物
格隆匯4月24日丨亞輝龍(688575.SH)公佈,公司擬與公司關聯方肖育勁先生及瑞龍康泰共同出資人民幣500萬元設立煥生紀生物。其中,亞輝龍以自有資金出資人民幣200萬元,佔煥生紀生物註冊資本的40%;瑞龍康泰出資人民幣200萬元,佔煥生紀生物註冊資本的40%;肖育勁先生出資人民幣100萬元,佔煥生紀生物註冊資本的20%。根據《中華人民共和國公司法》(以下簡稱“《公司法》”)《上海證券交易所科創板股票上市規則》(以下簡稱“《科創板上市規則》”)等法律法規和《深圳市亞輝龍生物科技股份有限公司章程》(以下簡稱“《公司章程》”)的相關規定,因肖育勁先生為公司副總經理,且瑞龍康泰為肖育勁先生擔任普通合夥人的企業,本次投資事項構成公司與關聯方共同投資的關聯交易情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.